IBO stock forecast, quote, news & analysis
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases... Show more
Why Impact BioMedical (IBO) Stock Is Down -31.5% in the Last 30 Days
Key Takeaways
- IBO shares fell roughly 31.5% over the trailing 30 days, from about $5.81 to $3.98 on a split-adjusted basis.
- The decline followed a 1-for-12.62 reverse stock split that took effect September 23, 2026, and a sharp mid-September spike tied to merger news.
- The company is pursuing a business combination with Zoar Ltd., a global pharmaceutical manufacturer focused on active pharmaceutical ingredients and intermediates.
- Over the trailing quarter, the stock is down approximately 34%, reflecting sustained post-split selling pressure.
- Impact BioMedical remains a pre-revenue, early-stage company with minimal reported revenue and recurring net losses.
Impact BioMedical (IBO) Company Overview and Market Position
Impact BioMedical, Inc. (NYSE American: IBO) is a Houston, Texas-based holding company that discovers, validates, and patents proprietary technologies for potential applications in specialty biopharmaceuticals and consumer healthcare and wellness. Through subsidiaries such as Global BioLife, the company pursues research in areas including neurological, oncological, and immune-related conditions, as well as open-air defense initiatives aimed at curbing airborne infectious diseases such as tuberculosis and influenza.
The company operates through research, licensing, co-development, joint ventures, and other partnerships rather than as a traditional commercial-stage drugmaker. With minimal reported revenue and a small public float, IBO is widely followed as a speculative micro-cap biotech name whose valuation is driven primarily by corporate developments and sentiment rather than near-term fundamentals.
Impact BioMedical (IBO) Stock Price Performance: Last 30 Days vs. Quarter
On a split-adjusted basis, IBO closed near $5.81 in mid-September and finished at $3.98 by mid-October, a decline of roughly 31.5% over the trailing 30 days. The move was not linear: the stock rallied to a peak close of about $7.45 in mid-September as merger-related headlines emerged, before giving back those gains and then some in the weeks that followed.
Zooming out to the trailing quarter, the picture is similarly negative. From a level near $6.06 in mid-July, the stock has fallen approximately 34%, reflecting a multi-month downtrend punctuated by a brief, volatile September spike around the reverse-split and merger announcements.
What Drove IBO Stock Price in the Last 30 Days
The dominant catalyst was corporate action. On September 11, 2026, the company announced a 1-for-12.62 reverse stock split intended to support its continued-listing objectives and its proposed merger with Zoar Ltd. (formerly Dr Ashley's Limited). A corrected release on September 14 clarified that Impact stockholders would receive one Zoar share for each Impact share held immediately before the merger, correcting an earlier misstatement of a 1-for-4 exchange ratio.
The reverse split took effect September 23, 2026, reducing the outstanding share count from roughly 107.8 million to about 8.5 million. While the announcement initially lifted the shares, the post-split period saw sustained selling pressure — a pattern frequently observed when reverse splits are used for listing compliance and when a company's underlying fundamentals remain weak. The stock slid from its September peak through October, leaving the 30-day return deeply negative.
What Drove IBO Stock Performance Over the Last Quarter
The broader three-month trend reflects the same theme: a micro-cap restructuring its capital structure and pursuing a transformative merger while generating minimal operating revenue. Zoar Ltd., a global pharmaceutical company focused on active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing, has filed a Form F-4 registration statement with the SEC containing a preliminary proxy statement and prospectus. DSS, Inc., a significant stockholder, has publicly referenced the filing.
Investor enthusiasm around the potential combination produced a sharp but short-lived rally, yet the stock's inability to hold those gains — combined with the mechanical share reduction and lingering uncertainty over deal completion — drove the net quarterly decline.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing and most relevant AI trading bots. While Tickeron offers hundreds of AI bots that trade thousands of tickers, only those meeting its performance and relevance criteria appear in this section. The bots differ widely in strategy, timeframe, and performance metrics, allowing traders to explore approaches ranging from short-term momentum to longer-horizon patterns. Reviewing these tools can help investors identify AI-driven signals and diversify the way they monitor market opportunities.
IBO Stock Forecast Drivers: What Investors Should Watch Next
The primary near-term catalyst is the status of the Zoar Ltd. merger. Investors should monitor whether the SEC declares the Form F-4 effective, whether Impact stockholders approve the transaction, and whether Zoar's ordinary shares gain approval for listing on NYSE American. Any delay, amendment, or termination of the agreement could materially affect the stock.
Beyond the deal, watch for updates on the company's continued-listing status, cash position, and funding needs given its minimal revenue and recurring losses. Macro conditions affecting speculative micro-cap and biotech sentiment may also influence trading. These factors carry meaningful risk, and the company has stated that the reverse split does not guarantee listing compliance or deal completion.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for IBO turns negative, indicating new downward trend
IBO saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 36 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IBO turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In 13 of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IBO moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBO crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
IBO broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IBO entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBO's RSI Oscillator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 18 of 28 cases where IBO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
Following a +31.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBO advanced for three days, in 72 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 8 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.190) is normal, around the industry mean (2.988). P/E Ratio (0.362) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1111.111) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. IBO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology